Predictors of hyperkalemia and death in patients with cardiac and renal disease.

[1]  Akshay S. Desai,et al.  Hyperkalemia in patients with heart failure: Incidence, prevalence, and management , 2009, Current heart failure reports.

[2]  M. Valsecchi,et al.  Sudden death and associated factors in a historical cohort of chronic haemodialysis patients. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  M. Zhan,et al.  The frequency of hyperkalemia and its significance in chronic kidney disease. , 2009, Archives of internal medicine.

[4]  B. Wożakowska-Kapłon,et al.  Iatrogenic hyperkalemia as a serious problem in therapy of cardiovascular diseases in elderly patients. , 2009, Polskie Archiwum Medycyny Wewnetrznej.

[5]  L. Ruilope,et al.  Serum Potassium and Clinical Outcomes in the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) , 2008, Circulation.

[6]  M. Al-mallah,et al.  Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. , 2008, Journal of cardiac failure.

[7]  Akshay S. Desai,et al.  Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. , 2007, Journal of the American College of Cardiology.

[8]  H. Krumholz,et al.  Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. , 2007, Archives of internal medicine.

[9]  A. Ducharme,et al.  Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. , 2006, American heart journal.

[10]  Ambreen Gul,et al.  Cardiovascular risk factors in chronic kidney disease. , 2005, Kidney international.

[11]  F. Luft,et al.  The Mineralocorticoid Receptor and Oxidative Stress , 2005, Heart Failure Reviews.

[12]  A. Laupacis,et al.  Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study , 2004 .

[13]  A. Struthers,et al.  What is the optimal serum potassium level in cardiovascular patients? , 2004, Journal of the American College of Cardiology.

[14]  K. Weber,et al.  Aldosteronism and Peripheral Blood Mononuclear Cell Activation: A Neuroendocrine-Immune Interface , 2003, Circulation research.

[15]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[16]  G. Eknoyan,et al.  National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.

[17]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  N. Hollenberg.  ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. , 2001, Current hypertension reports.

[19]  S. Yusuf,et al.  Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial , 2001, Annals of Internal Medicine.

[20]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[21]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[22]  R. DeFronzo,et al.  Hyperkalemia and hyporeninemic hypoaldosteronism. , 1980, Kidney international.